Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Evaluation of vascular smooth muscle and corpus cavernosum on hypercholesterolemia. Is resveratrol promising on erectile dysfunction?

Abstract

The aim of this study is to evaluate the effects of hypercholesterolemia in thoracic aorta (TA), mesenteric artery (MA), renal artery (RA), and corpus cavernosum (CC) isolated from cholesterol-fed rabbits. For determination of the maximum detrimental effect, vasorelaxation and vasoconstriction results of arteries and CC have been compared. Animals were fed with a diet that contained 2% w/w cholesterol and 2% w/w high cholesterol plus resveratrol (4 mg kg–1 per day) for 6-week duration. Total cholesterol levels in the plasma were measured. Vascular and endothelial functions in RA, TA, MA, and CC were assessed by isolated tissue bath with cumulative doses of acetylcholine and sodium nitroprusside. The statistical significance of differences of groups was analyzed by means of one-way ANOVA or Student's t-test. P-values <0.05 were considered significant. There have been no significant changes on plasma total cholesterol levels between cholesterol and cholesterol + resveratrol-treated groups. Vasorelaxation responses to acetylcholine in resveratrol-treated group showed significant changes when compared with hypercholesterolemic group. No statistically significant differences were seen between non-receptor-mediated vasorelaxation responses between the three groups. Resveratrol might be an effective treatment in the prevention of atherosclerotic changes in arteries and CC. The initial effects of hypercholesterolemia on erectile dysfunction and endothelial dysfunction may be precluded with resveratrol. This protective effect may also ensure the prevention of coronary arterial diseases and renovascular diseases in hypercholesterolemic patients.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4

References

  1. Montorsi F, Briganti A, Salonia A, Rigatti P, Margonato A, Macchi A et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003; 44: 360–364.

    Article  Google Scholar 

  2. Kloner RA, Mullin SH, Shook T, Matthews R, Mayeda G, Burstein S et al. Erectile dysfunction in the cardiac patient: how common and should we treat? J Urol 2003; 170: 46–50.

    Article  Google Scholar 

  3. Solomon H, Man JW, Wierzbicki AS, Jackson G . Relation of erectile dysfunction to angiographic coronary artery disease. Am J Cardiol 2003; 91: 230–231.

    Article  Google Scholar 

  4. Min JK, Williams KA, Okwuosa TM, Bell GW, Panutich MS, Ward RP . Prediction of coronary heart disease by erectile dysfunction in men referred for nuclear stress testing. Arch Intern Med 2006; 166: 201–206.

    Article  Google Scholar 

  5. Ponholzer A, Temml C, Obermayr R, Wehrberger C, Madersbacher S . Is erectile dysfunction an indicator for increased risk of coronary heart disease and stroke? Eur Urol 2005; 48: 512–518.

    Article  Google Scholar 

  6. Gazzaruso C, Giordanetti S, De Amici E, Bertone G, Falcone C, Geroldi D et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 2004; 110: 22–26.

    Article  Google Scholar 

  7. Vlachopoulos C, Rokkas K, Ioakeimidis N, Aggeli C, Michaelides A, Roussakis G et al. Prevalence of asymptomatic coronary artery disease in men with vasculogenic erectile dysfunction: a prospective angiographic study. Eur Urol 2005; 48: 996–1002.

    Article  Google Scholar 

  8. Gotto AM, Grundy SM . Lowering LDL-cholesterol: questions from recent analysis of clinical trials. Data from the Interdisciplinary Council of Reducing the Risk for Coronary Heart Disease. Circulation 1999; 99: 1–7.

    Article  Google Scholar 

  9. Shindel AW, Kishore S, Lue TF . Drugs designed to improve endothelial function: effects on erectile dysfunction. Curr Pharm Des 2008; 14: 3758–3767.

    CAS  Article  Google Scholar 

  10. Schmitz G, Langmann T . Pharmacogenomics of cholesterol-lowering therapy. Vascul Pharmacol 2006; 44: 75–89.

    CAS  Article  Google Scholar 

  11. Kalsi JS, Ralph DJ, Thomas P, Bellringer J, Minhas S, Kell PD et al. A nitric oxide-releasing PDE5 inhibitor relaxes human corpus cavernosum in the absence of endogenous nitric oxide. J Sex Med 2005; 2: 53–57.

    CAS  Article  Google Scholar 

  12. Ghatta S, Ramarao P . Increased contractile responses to 5-hydroxytryptamine and Angiotensin II in high fat diet fed rat thoracic aorta. Lipids Health Dis 2004; 3: 19.

    Article  Google Scholar 

  13. Macovei L . Pleiotropic effects of therapy in endothelial dysfunction syndrome. Rev Med Chir Soc Med Nat Iasi 2004; 108: 17–22.

    CAS  PubMed  Google Scholar 

  14. Kensey KR . The mechanistic relationships between hemorheological characteristics and cardiovascular disease. Curr Med Res Opin 2003; 19: 587–596.

    Article  Google Scholar 

  15. Shi Q, Vandeberg JF, Jett C, Rice K, Leland MM, Talley L et al. Arterial endothelial dysfunction in baboons fed a high-cholesterol, high-fat diet. Am J Clin Nutr 2005; 82: 751–759.

    CAS  Article  Google Scholar 

  16. Vane JR, Anggard EE, Botting RM . Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323: 27–36.

    CAS  Article  Google Scholar 

  17. Kang SY, Kim SH, Schini VB, Kim ND . Dietary ginsenosides improve endothelium-dependent relaxation in the thoracic aorta of hypercholesterolemic rabbit. Gen Pharmacol 1995; 26: 483–487.

    CAS  Article  Google Scholar 

  18. Müller S, König I, Meyer W, Kojda G . Inhibition of vascular oxidative stress in hypercholesterolemia by eccentric isosorbide mononitrate. J Am Coll Cardiol 2004; 44: 624–631.

    Article  Google Scholar 

  19. Sanz M, Ganado P, Tejerina T . Two angiotensin AT1 receptor antagonists, irbesartan and losartan, effects in cholesterol-fed rabbits. Eur J Pharmacol 2002; 442: 99–106.

    CAS  Article  Google Scholar 

  20. Lenich CM, Chobanian AV, Brecher P, Zannis VI . Effect of dietary cholesterol and alloxan-diabetes on tissue cholesterol and apolipoprotein E mRNA levels in the rabbit. J Lipid Res 1991; 32: 431–438.

    CAS  PubMed  Google Scholar 

  21. Penumathsa SV, Thirunavukkarasu M, Koneru S, Juhasz B, Zhan L, Pant R et al. Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J Mol Cell Cardiol 2007; 42: 508–516.

    CAS  Article  Google Scholar 

  22. Wang Z, Zou J, Cao K, Hsieh TC, Huang Y, Wu JM . Dealcoholized red wine containing known amounts of resveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels. Int J Mol Med 2005; 16: 533–540.

    CAS  PubMed  Google Scholar 

  23. Wilson T, Knight TJ, Beitz DC, Lewis DS, Engen RL . Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Life Sci 1996; 59: 15–21.

    Article  Google Scholar 

  24. Safian RD, Textor SC . Renal-artery stenosis. N Engl J Med 2001; 344: 431–442.

    CAS  Article  Google Scholar 

  25. Piepot HA, Groeneveld AB, van Lambalgen AA, Sipkema P . Endotoxin impairs endothelium-dependent vasodilation more in the coronary and renal arteries than in other arteries of the rat. J Surg Res 2003; 110: 413–418.

    CAS  Article  Google Scholar 

  26. Moncada S, Higgs EA . Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J 1995; 9: 1319–1330.

    CAS  Article  Google Scholar 

  27. Furchgott RF . Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. Biosci Rep 1999; 19: 235–251.

    CAS  Article  Google Scholar 

  28. Jaiswal N, Lambrecht G, Mutschler E, Tacke R, Malik KU . Pharmacological characterization of the vascular muscarinic receptors mediating relaxation and contraction in rabbit aorta. J Pharmacol Exp Ther 1991; 258: 842–850.

    CAS  PubMed  Google Scholar 

  29. Fisher Jr DF, Fry WJ . Collateral mesenteric circulation. Surg Gynecol Obstet 1987; 164: 487–492.

    PubMed  Google Scholar 

  30. AbuRahma AF, Stone PA, Bates MC, Welch CA . Angioplasty/stenting of the superior mesenteric artery and celiac trunk: early and late outcomes. J Endovasc Ther 2003; 10: 1046–1053.

    Article  Google Scholar 

  31. White CR, Parks DA, Patel RP, Shelton J, Tarpey MM, Freeman BA et al. L-Arginine inhibits xanthine oxidase-dependent endothelial dysfunction in hypercholesterolemia. FEBS Lett 2004; 561: 94–98.

    CAS  Article  Google Scholar 

  32. McCullough AR . The penis as a barometer of endothelial health. Rev Urol 2003; 5: 3–8.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S Gidener.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Soner, B., Murat, N., Demir, O. et al. Evaluation of vascular smooth muscle and corpus cavernosum on hypercholesterolemia. Is resveratrol promising on erectile dysfunction?. Int J Impot Res 22, 227–233 (2010). https://doi.org/10.1038/ijir.2010.8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2010.8

Keywords

  • corpus cavernosum
  • resveratrol
  • erectile dysfunction

This article is cited by

Search

Quick links